Literature DB >> 18190874

Lessons from the "Euro-Phospholipid" project.

Ricard Cervera1.   

Abstract

The "Euro-Phospholipid" project started in 1999 with a multicentre, consecutive and prospective design. A total cohort of 1000 patients with antiphospholipid syndrome (APS), derived from 13 countries (Belgium, Bulgaria, Denmark, France, Germany, Greece, Hungary, Israel, Italy, the Netherlands, Portugal, Spain and United Kingdom), has been followed since then by a European consortium that was created as part of the network promoted by the "European Forum on Antiphospholipid Antibodies", a study group devoted to the development of multicentre projects with large populations of APS patients. This project allowed the identification of the prevalence and characteristics of the main clinical and immunological manifestations at the onset and during the evolution of APS and demonstrated that it is possible to recognize more homogeneous subsets of clinical significance.

Entities:  

Mesh:

Year:  2007        PMID: 18190874     DOI: 10.1016/j.autrev.2007.11.011

Source DB:  PubMed          Journal:  Autoimmun Rev        ISSN: 1568-9972            Impact factor:   9.754


  7 in total

1.  Cardiovascular Considerations in Anesthetic Management for a Patient With Antiphospholipid Syndrome and Decreased Cardiac Function: A Case Study.

Authors:  Makiko Shibuya; Yukifumi Kimura; Shigeru Takuma; Nobuhito Kamekura Dds; Toshiaki Fujisawa
Journal:  Anesth Prog       Date:  2021-03-01

2.  Immunogenicity, safety, and antiphospholipid antibodies after SARS-CoV-2 vaccine in patients with primary antiphospholipid syndrome.

Authors:  Flavio Signorelli; Gustavo Guimarães Moreira Balbi; Nadia E Aikawa; Clovis A Silva; Léonard de Vinci Kanda Kupa; Ana C Medeiros-Ribeiro; Emily Fn Yuki; Sandra G Pasoto; Carla Gs Saad; Eduardo F Borba; Luciana Parente Costa Seguro; Tatiana Pedrosa; Vitor Antonio de Angeli Oliveira; Ana Luisa Cerqueira de Sant'Ana Costa; Carolina T Ribeiro; Roseli Eliana Beseggio Santos; Danieli Castro Oliveira Andrade; Eloisa Bonfá
Journal:  Lupus       Date:  2022-05-20       Impact factor: 2.858

Review 3.  Catastrophic antiphospholipid syndrome: treatment, prognosis, and the risk of relapse.

Authors:  Silvia Bucciarelli; Doruk Erkan; Gerard Espinosa; Ricard Cervera
Journal:  Clin Rev Allergy Immunol       Date:  2009-06       Impact factor: 8.667

Review 4.  Management of the antiphospholipid syndrome.

Authors:  Gerard Espinosa; Ricard Cervera
Journal:  Auto Immun Highlights       Date:  2010-07-10

5.  Antiphospholipid-related chorea.

Authors:  Silvio Peluso; Antonella Antenora; Anna De Rosa; Alessandro Roca; Gennaro Maddaluno; Vincenzo Brescia Morra; Giuseppe De Michele
Journal:  Front Neurol       Date:  2012-10-22       Impact factor: 4.003

Review 6.  Antiphospholipid syndrome.

Authors:  Gerard Espinosa; Ricard Cervera
Journal:  Arthritis Res Ther       Date:  2008-12-15       Impact factor: 5.156

7.  A polymorphism in TLR2 is associated with arterial thrombosis in a multiethnic population of patients with systemic lupus erythematosus.

Authors:  Rachel Kaiser; Ling Fung Tang; Kimberly E Taylor; Kirsten Sterba; Joanne Nititham; Elizabeth E Brown; Jeffrey C Edberg; Gerald McGwin; Graciela S Alarcón; Rosalind Ramsey-Goldman; John D Reveille; Luis M Vilá; Michelle Petri; Joyce Rauch; Emily Miller; Kara Mesznik; Pui-Yan Kwok; Robert P Kimberly; Jane E Salmon; Lindsey A Criswell
Journal:  Arthritis Rheumatol       Date:  2014-07       Impact factor: 10.995

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.